JP2025503015A5 - - Google Patents

Info

Publication number
JP2025503015A5
JP2025503015A5 JP2024543009A JP2024543009A JP2025503015A5 JP 2025503015 A5 JP2025503015 A5 JP 2025503015A5 JP 2024543009 A JP2024543009 A JP 2024543009A JP 2024543009 A JP2024543009 A JP 2024543009A JP 2025503015 A5 JP2025503015 A5 JP 2025503015A5
Authority
JP
Japan
Prior art keywords
beta
cyp11β2
subject
hydroxylase inhibitor
serum
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2024543009A
Other languages
English (en)
Japanese (ja)
Other versions
JP2025503015A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/IB2023/050444 external-priority patent/WO2023139506A1/en
Publication of JP2025503015A publication Critical patent/JP2025503015A/ja
Publication of JP2025503015A5 publication Critical patent/JP2025503015A5/ja
Pending legal-status Critical Current

Links

JP2024543009A 2022-01-19 2023-01-19 アルドステロン合成酵素を周期的に抑制することによる高血圧症の治療方法 Pending JP2025503015A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US202263300967P 2022-01-19 2022-01-19
US63/300,967 2022-01-19
US202263400301P 2022-08-23 2022-08-23
US63/400,301 2022-08-23
PCT/IB2023/050444 WO2023139506A1 (en) 2022-01-19 2023-01-19 Methods of treating hypertension by periodic suppression of aldosterone synthase

Publications (2)

Publication Number Publication Date
JP2025503015A JP2025503015A (ja) 2025-01-30
JP2025503015A5 true JP2025503015A5 (cg-RX-API-DMAC7.html) 2026-01-26

Family

ID=87347916

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2024543009A Pending JP2025503015A (ja) 2022-01-19 2023-01-19 アルドステロン合成酵素を周期的に抑制することによる高血圧症の治療方法

Country Status (7)

Country Link
US (1) US20250099475A1 (cg-RX-API-DMAC7.html)
EP (1) EP4466021A4 (cg-RX-API-DMAC7.html)
JP (1) JP2025503015A (cg-RX-API-DMAC7.html)
KR (1) KR20240140102A (cg-RX-API-DMAC7.html)
CA (1) CA3240577A1 (cg-RX-API-DMAC7.html)
TW (1) TW202339758A (cg-RX-API-DMAC7.html)
WO (1) WO2023139506A1 (cg-RX-API-DMAC7.html)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4577217A4 (en) * 2022-08-23 2026-08-12 Mineralys Therapeutics Inc METHODS OF TREATING HYPERTENSION WITH A COMBINATION OF AN ALDOSTERONE SYNTHASE INHIBITOR AND A DIURETIC
KR20250053914A (ko) * 2022-08-23 2025-04-22 미네랄리스 테라퓨틱스, 아이엔씨. 비만 대상체에서 고혈압을 치료하는 방법

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9550750B2 (en) * 2012-10-05 2017-01-24 Merck Sharp & Dohme Corp. Indoline compounds as aldosterone synthase inhibitors
WO2014179186A1 (en) * 2013-04-30 2014-11-06 Boehringer Ingelheim International Gmbh Aldosterone synthase inhibitors
MY176401A (en) * 2014-04-24 2020-08-05 Mitsubishi Tanabe Pharma Corp Novel disubstituted 1,2,4-triazine compound
US20240009201A1 (en) * 2020-10-26 2024-01-11 Mineralys Therapeutics, Inc. Cyp11b2 beta hydroxylase inhibitors for hypertension

Similar Documents

Publication Publication Date Title
RU2324482C2 (ru) Комбинация органических соединений
EP4212152B1 (en) Sacubitril-valsartan dosage regimen for treating chronic systolic heart failure
JP2023546970A5 (cg-RX-API-DMAC7.html)
BRPI0306907B1 (pt) composição farmacêutica, que compreende valsartan e inibidor de nep ou seus sais
TW200831078A (en) Angiotensin II receptor antagonist for the prevention or treatment of systemic diseases in cats
EP2837380B1 (en) Lercanidipine hydrochloride and losartan potassium compound preparation and preparation method thereof
JP2002535367A5 (cg-RX-API-DMAC7.html)
EP1307192B1 (en) Candesartan for treating migraine
EP4344701A1 (en) Pharmaceutical composition comprising 1-(3-cyano-1-isopropyl-indol-5-yl)pyrazole-4-carboxylic acid
EP4477223A1 (en) Pharmaceutical composition comprising allopurinol, febuxostat or pharmaceutically acceptable salt thereof for prevention or treatment of chronic kidney disease in subject having high blood uric acid concentration
JP6726138B2 (ja) (3s,3s’)4,4’−ジスルファンジイルビス(3−アミノブタン 1−スルホン酸)および第2の抗高血圧剤の組合せ
US12336978B2 (en) Pharmaceutical composition containing amlodipine, chlorthalidone, and amiloride and application thereof
Mimran et al. Maintenance of the antihypertensive efficacy of captopril despite consistent reduction in daily dosage.
Waller Drugs for heart failure and arrhythmias
RU2024126016A (ru) Лечение глиомы низкой степени злокачественности мирдаметинибом
EP1841434A1 (en) Combination therapy for treating heart disease
EP2482658B1 (en) Methods and compositions for treatment of raynaud's phenomenon
JPS61200917A (ja) ベタキソロールとニフエジピンとを含有する医薬組成物
Kochar Hypertension—An Overview
Tang et al. P-257: Levamlodipine therapy for hypertension after kidney transplantation
KANTILAL COMPARISON OF FOSINOPRIL, AND PROPRANOLOL, COMBINED WITH CHLORTHALIDONE IN THE TREATMENT OF MODERATELY TO SEVERELY HYPERTENSIVE BLACK AND
CA3156536A1 (en) Treatment of diabetic nephropathy with an sgc stimulator
WO2005074928A1 (ja) 高血圧症治療薬
HK1148477A (en) Combination of organic compounds
HK1053609B (en) Candesartan for treating migraine